We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

By LabMedica International staff writers
Posted on 29 Mar 2015
Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies).”

MS is the most powerful tool in proteomic biomarker discovery and validation. More...
Through its traditional techniques MS has struggled to elucidate tissue molecular distribution related to disease state. In recent years, MS imaging, including MALDI and DESI imaging, has seen significant application in proteomic biomarker discovery with its distinct advantages in preservation of spatial proteomic data and potential to improve assay reproducibility.

In MALDI and DESI, nondestructive techniques are utilized with soft ionization sources to desorb and ionize surface molecules for MS analysis. According to Kalorama, one of the key strengths of MALDI and DESI is that they avoid traditional tissue sample preparation, a tedious front-end process that presents a significant bottleneck in proteomics where differential analysis is used to compare protein expression and abundance between samples. Proteolytic digestion and other sample preparation procedures remove significant analytical context value related to protein spatial distribution and concentration.

Kalorama believes that a number of studies have cemented the reputation of these MS technologies. Researchers have noted the novelty of MALDI imaging of tissue (introduced in 1997) to discover proteins otherwise difficult to separate by electrophoresis or hidden in shotgun proteomic processes that are biased towards higher-mass proteins. Recent studies have used MALDI imaging to discover several biomarkers associated with gastric cancer survival prognosis, forms of ovarian cancer, and to develop a novel grading system for papillary non-invasive bladder cancer.

Kalorama’s report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.

Related Links:

Kalorama Information
Proteomics Markets for Research and IVD Applications, report



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.